Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome. (4th March 2019)

• Record Type: Journal Article
• Authors: Olden, Kevin W.; Chey, William D.; Shringarpure, Reshma; Paul Nicandro, Jean; Chuang, Emil; Earnest, David L.
• Is Part Of: Current medical research and opinion. Volume 35:Number 3(2019)
• Page Start: 461
• Page End: 472
• Publication Date: 2019-03-04
• Subjects: Alosetron versus traditional therapy -- quality of life -- severe diarrhea-predominant irritable bowel syndrome -- symptom improvement -- work productivity; Clinical medicine -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1080/03007995.2018.1533456
• Languages: English
• ISSNs: 0300-7995

Abstract

Abstract: Objective: Severe diarrhea-predominant irritable bowel syndrome (IBS-D) is associated with decreased health-related quality of life (HRQOL) and increased health care costs. Treatment recommendations for IBS-D often start with traditional pharmacotherapy (TP), with escalation to alosetron, rifaximin or eluxadoline if there is no success. There has been no previous head-to-head clinical trial comparing IBS-D treatment outcome for alosetron versus TP. This study, GSK protocol S3B30020, evaluated resource use, work productivity, health-related quality of life and global symptom response in women with IBS-D who were treated with alosetron or TP. Methods: A total of 1956 patients who met criteria for severe IBS-D were randomized to treatment with alosetron 1 mg twice daily (BID) or only TP for up to 24 weeks. Work productivity and resource use were evaluated by standard questionnaires, HRQOL by the IBSQOL instrument and IBS symptoms by the Global Improvement Scale (GIS). Results: Compared to only TP, alosetron-treated patients reported: (1) fewer clinic/office visits for any health problem ( p = .0181) or for IBS-D ( p = .0004); (2) reduced use of over-the-counter medications for IBS-D ( p < .0001); (3) fewer days of lost work productivity ( p < .0001); (4) decreased restriction of social and outdoor activities ( p < .0001); and (5) greater global improvement in IBS-D symptoms ( p < .0001). Alosetron treatment improved HRQOL scores for all domains ( p < .0001). Incidence of adverse events during alosetron use was not remarkable and was similar to that previously reported. Conclusions: Alosetron 1 mg BID significantly reduced health care utilization and lost productivity, and significantly improved global IBS symptoms, HRQOL, and participation in outdoor and social activities compared with treatment response to TP.